Soligenix Q1 FY26 net loss narrows to $2.8 million; reports no revenue

Soligenix, Inc.

Soligenix, Inc.

SNGX

0.00
  • Soligenix posted a net loss of $2.8 million, or $0.28 per share, for quarter ended March 31, 2026, narrowing from a $3 million loss a year earlier.
  • Research and development expense edged down to $1.8 million from $1.9 million, while general and administrative expense was flat at $1.1 million.
  • Cash was about $6 million as of March 31, 2026, with runway into second quarter 2027.
  • Phase 3 FLASH2 trial of HyBryte in cutaneous T-cell lymphoma was halted for futility following interim efficacy analysis; CEO Christopher J. Schaber said company will analyze data for potential patient subsets and may pursue follow-up talks with EMA and FDA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605080730PR_NEWS_USPR_____PH54668) on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.